Clinical Trial

A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002)

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
Researchers are looking for new vaccines to prevent pneumococcal disease, which is any infection in the lungs or other parts of the body that is caused by a type of bacteria called Streptococcus pneumoniae. V118C is a new vaccine designed to help prevent disease from Streptococcus pneumoniae bacteria. This study will look at V118C in toddlers and infants. The goal of the study is to learn how safe V118C is for children and how well they tolerate it.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2025-12-10; most recent amendment 2026-04-15.
Status change: Not Yet Recruiting → Recruiting 2026-01-19
Trial Details
NCT Number NCT07300267
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Pneumococcal Infection
Enrollment 210 participants
Start Date 2026-01-13
Primary Completion 2028-10-24 (estimated)
Study Completion 2029-05-25 (estimated)
Updated on ClinicalTrials.gov 2026-04-17